KNSA Archives - BioTuesdays

Developments

Kiniksa Pharma initiates dosing in Phase 2b prurigo nodularis trial

Kiniksa Pharmaceuticals (NASDAQ:KNSA) initiated dosing in its Phase 2b trial evaluating vixarelimab for the treatment of prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...

December 15, 2020

Developments

Kiniksa mavrilimumab gets FDA orphan drug designation for giant cell arteritis

Kiniksa Pharma’s (NASDAQ:KNSA) mavrilimumab received FDA orphan drug designation for the treatment of giant cell arteritis (GCA). GCA is a chronic inflammatory disease of medium-to-large arteries, which can result in...

September 15, 2020

Developments

Kiniksa Pharma reports positive Phase 3 rilonacept data in pericarditis

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) rilonacept met its primary and major secondary efficacy endpoints in a Phase 3 recurrent pericarditis trial. The trial met its primary endpoint of time to pericarditis recurrence...

June 29, 2020

Developments

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported updated data from its open-label study of mavrilimab for the treatment of COVID-19-related pneumonia, as well as its Phase 2 trial for vixarelimab for the treatment of...

May 11, 2020

Developments

Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) vixarelimab met its primary efficacy endpoint in Phase 2a trial in patients with prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...

April 22, 2020

Developments

Kiniksa Pharma’s rilonacept gets FDA breakthrough therapy designation for pericarditis

The FDA granted Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) rilonacept breakthrough therapy designation for the treatment of recurrent pericarditis. Rilonacept is a recombinant fusion protein that blocks inflammatory...

November 20, 2019

Tag - KNSA

Kiniksa Pharma initiates dosing in Phase 2b prurigo nodularis trial

Kiniksa mavrilimumab gets FDA orphan drug designation for giant cell arteritis

Kiniksa Pharma reports positive Phase 3 rilonacept data in pericarditis

Kiniksa Pharma updates data from COVID-19, chronic pruritis studies

Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

Kiniksa Pharma’s rilonacept gets FDA breakthrough therapy designation for pericarditis

General

More